Radiopharm Theranostics (ASX: RAD) has announced that patient enrollment has commenced for the third cohort of its ongoing Phase 1 dose-escalation trial evaluating 177Lu-RAD204, a radiolabeled single-domain antibody targeting PD-L1 in advanced solid tumours. …
Radiopharm Theranostics advances Phase 1 trial of 177Lu-RAD204 in PD-L1 positive cancers
November 12, 2025 Australian Biotech
Latest Video
New Stories
-
Australians open to AI in healthcare, but prefer doctors to be in control
November 13, 2025 - - Latest News -
Every Government agency to appoint a 'Chief AI Officer' under national plan
November 12, 2025 - - Latest News -
New Zealand accelerates medicines reform with major regulatory changes
November 12, 2025 - - Latest News -
FDA moves to lift long-standing hormone therapy warnings in major shift for women’s health
November 12, 2025 - - Latest News -
Optometry Australia and Alcon launch scholarship fund to support First Nations eye health leaders
November 12, 2025 - - Latest News -
Radiopharm Theranostics advances Phase 1 trial of 177Lu-RAD204 in PD-L1 positive cancers
November 12, 2025 - - Australian Biotech -
Arovella appoints former CSL Chief Scientific Officer Dr Andrew Nash to its Board
November 12, 2025 - - Australian Biotech